Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)

BACKGROUND: The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors were confirmed by several clinical trials, but its effectiveness in routine clinical practice in China has not been evaluated. This study aims to describe the real world effectiveness of PCSK-9 i...

Descripción completa

Detalles Bibliográficos
Autores principales: LIU, Yu-Qi, LI, Dan-Dan, CHAI, Meng, CONG, Hong-Liang, CONG, Xiao-Qiang, DAI, Jun, DU, Rong-Pin, GAO, Ming, GUO, Jin-Cheng, GUO, Yan-Qing, HONG, Xiao-Jian, HUANG, Rong-Chong, JIA, Feng-Shun, LI, Jia-Yu, LI, Qing, LIU, Jia-Mei, LIU, Xin-Ping, LIU, Yu-Guo, NIE, Hong-Gang, SHAO, Bing, SHEN, Xiao-Yu, SONG, Hai-Qing, SONG, Yi-Jun, WANG, Li-Jun, WANG, Shuo, WU, Dong-Mei, XIA, Jing, YANG, Zhi-Yong, YU, Hong-Ying, ZHANG, Hui, ZHANG, Tie-Mei, ZHAO, Ji-Yi, ZHAO, Liang-Chen, ZHENG, Ming-Qi, CHEN, Yun-Dai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100428/
https://www.ncbi.nlm.nih.gov/pubmed/33995505
http://dx.doi.org/10.11909/j.issn.1671-5411.2021.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100428/
https://www.ncbi.nlm.nih.gov/pubmed/33995505
http://dx.doi.org/10.11909/j.issn.1671-5411.2021.04.005

Ejemplares similares